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Abstract  
Background and aims Tobacco and cannabis are commonly co-used, and evidence for the influence 
of co-use on quit outcomes for either substance is mixed. We sought to determine the efficacy of 
tobacco and/or cannabis use interventions, delivered to co-users, on cannabis and tobacco use 
outcomes.  
Method Systematic review with meta-analysis and narrative review, using five databases and author 
requests for co-use data.  Controlled and uncontrolled intervention studies focussing on treatment 
of tobacco and/or cannabis use assessing use of both pre and post intervention were included. 
Prevention interventions were excluded.  Bayesian meta-analysis was used across four outcome 
measures: risk ratio for tobacco and cannabis cessation post intervention separately; standardised 
mean change for tobacco and cannabis reduction post intervention separately. Narrative reporting 
of same outcome measures in non-randomised clinical trials (non-RCTs) and quality assessment of all 
included studies were conducted.   
Results Twenty studies (12 RCTs and 8 uncontrolled) were included. Bayesian meta-analysis with 
informative priors based on existing data of 11 RCTs (six single substance, five multi-substance 
interventions) delivered to co-users (n= up to 1117) showed weak evidence for an effect on cannabis 
cessation (risk ratio [RR]=1.48 [0.92,2.49], studies=8) and no clear effect on tobacco cessation (RR= 
1.10 [0.68,1.87], studies=9).  Subgroup analysis suggested multi-substance interventions might be 
more effective than cannabis targeted interventions on cannabis cessation (RR= 2.19 [1.10, 4.36] 
versus RR=1.39 [0.75,2.74]). A significant intervention effect was observed on cannabis reduction 
(0.25 [0.03, 0.45], studies =9) but not on tobacco reduction (0.06 [-0.11, 0.23], studies = 9). Quality 
of evidence was moderate, although measurement of co-use and of cannabis use requires 
standardisation. Uncontrolled studies targeting both cannabis and tobacco use indicated feasibility 
and acceptability.  
Conclusions Single and multi-substance interventions addressing tobacco and/or cannabis have not 
shown a clear effect on either tobacco or cannabis cessation and reduction amongst co-users. 
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Introduction  
Tobacco and cannabis are two of the most commonly used psychoactive substances worldwide and 
are frequently co-used but rarely co-treated in clinical interventions (1).   
Tobacco use remains the leading cause of preventable death and disease worldwide, and efforts are 
required to address the significant use disparity amongst people with co-occurring substance use in 
particular (2, 3). Cannabis use is also associated with significant harms, although the evidence base is 
not as established as that for tobacco related harms (4). Each substance poses distinct known harms 
but also potential aggregated harms (5), and the last few years have seen an increased focus on the 
relationship between tobacco and cannabis use.  
Tobacco is used by over 1.1 billion people worldwide (6), and cannabis by an estimated 188 million 
(7). Although globally tobacco prevalence is decreasing, use is increasing in some regions such as 
Africa (6). Cannabis prevalence appears stable in most of Europe and Australasia, though there are 
early indications it may be increasing in the United Kingdom (UK) and in the United States (US) (8-11) 
and may change with increasing legalisation. Co-use of tobacco amongst cannabis users is 
consistently two to three times higher than amongst tobacco only users (12).  
Co-use may comprise both substances in the same product, i.e. co-administration, or sequential use 
in a given time period, i.e. concurrent. Globally, types of co-use vary significantly; broadly speaking 
tobacco and cannabis are commonly co-administered in Europe and Australia, whereas concurrent 
use has been more frequent in other parts of the world, although there are indications that co-use 
and co-administration is increasing in the US (13). Changing regulatory environments and availability 
of electronic devices used to deliver both tobacco/nicotine and cannabis have created a rapidly 
evolving landscape for these two substances. It is important to understand how co-use is associated 
with risk of dependence and amongst which populations, and how co-use variation may influence 
cessation attempts for all types of combustible and other tobacco and cannabis products.  
The relationship between tobacco and cannabis appears synergistic, operating on both a 
physiological and psychological level (14). Tobacco use seems to be a feature in the development of 
cannabis use disorder (13, 15), and to negatively influence outcomes of cannabis use treatment 
interventions (16, 17). Similarly, cannabis use is associated with higher nicotine dependence, though 
the influence of cannabis use on tobacco cessation is mixed (18-21).  Amongst single substance 
interventions, little is known about the impact of co-use on outcomes, since studies may not 
measure use of both substances, nor the type of co-use practised. For example it is not known 
whether co-administration may lead to poorer outcomes for tobacco cessation in comparison to 
concurrent use (17). Further research into the nature of the relationship between tobacco and 
cannabis use and its impact on cessation outcomes is warranted.  
A significant body of evidence exists on tobacco cessation interventions, as indicated by the 82 
Cochrane Reviews on the topic. Combining pharmacotherapy with behavioural support is likely to be 
the most effective tobacco cessation method (22).  By contrast, the evidence base for cannabis use 
interventions is limited; only two Cochrane Reviews have been published, investigating psychosocial 
and pharmacotherapy interventions.  Evidence for the latter is incomplete and low quality (23). 
Combining interventions such as Motivational Enhancement Therapy (MET) or Cognitive Behaviour 
Therapy (CBT) with contingency management (CM)show some positive effects, but, as for other 
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Systematic reviews of digital interventions for cannabis use have identified a small reduction effect 
(25-27).   
Despite being commonly co-used, tobacco and cannabis use are rarely co-treated. Low rates of 
tobacco cessation in cannabis users may be partly explained by co-use, hence in addition to 
addressing co-use within single substance interventions, it is important to investigate what impact 
dual interventions may have on co-use. For those who co-administer tobacco and cannabis, the 
shared route of administration and overlapping withdrawal symptoms may act as cues to relapse of 
either substance indicating that the efficacy of dual or multi-substance interventions in comparison 
to single substance interventions warrants examination (14, 28-29). Additionally, compensatory use 
of one substance following cessation of the other is important to consider (30).  
Reviews of co-use have considered the potential for pharmacological treatments in dual 
interventions, for sequential or simultaneous interventions and the most relevant evidence from 
single substance use interventions (1, 14, 28). Although co-use interventions for African American 
populations have been reviewed (31), this is the first systematic review to date of interventions 
targeting or addressing co-use for all populations.  
Objectives 
This systematic review seeks to investigate the nature and strength of the evidence base for 
interventions which target both tobacco and cannabis use, or which assess change in use of both; 
and to estimate the efficacy of included interventions on cessation or reduction of both substances. 
Method 
This systematic review followed the Preferred Reporting Items for Systematic Reviews and Meta-
Analyses statement, PRISMA (32). The protocol was registered prior to commencing the review (33). 
Eligibility criteria 
Studies were included if they published, or reported measuring, level of use of tobacco and cannabis 
pre and post treatment intervention. Controlled or uncontrolled, pilot or feasibility studies of single, 
dual and multi-substance use interventions were included. Prevention interventions were excluded. 
No limits were placed on age, setting, duration or intervention type.  
Identification of studies 
Five databases were used: Embase; Web of Science; Medline; PsychINFO; and CINAHL. Reference 
lists from included studies and cited literature reviews were also searched.  
Search strategies were developed for each database using controlled vocabulary and keywords using 
a combination of terms relating to tobacco and tobacco use treatment and cannabis and cannabis 
use treatment.  Articles published from January 1990 to March 2019 written in English, French and 
Spanish were included. 1990 was selected as older literature is less consistent in measurement, 
particularly of cannabis. The Medline search strategy is shown in supplementary materials (S1).   
All searches and initial screening of abstracts for review were carried out by HW in July 2017 and 
repeated in January 2018 and March 2019. HW reviewed full articles, and MD and AM reviewed 
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Quality assessment 
The Cochrane Risk of Bias assessment tool was used to evaluate the quality of included RCTs (34).  
Relevant items from the Russell Standard for tobacco studies were used to assess quality of tobacco 
use reporting (35). Uncontrolled studies were reviewed using Law’s Critical Review Form (36). HW 
carried out the quality reviews, and MD reviewed five of these. 
Funnel plots, including trim and fill where indicated, were used to assess publication bias and 
potential missing studies.  
Outcome measures 
The primary outcomes were change in use of tobacco and cannabis, measured either by cessation or 
reduction in use. Each study therefore had potentially four outcome measures of interest: tobacco 
cessation rate; cannabis cessation rate; tobacco reduction rate; cannabis reduction rate. Some 
studies also reported a fifth outcome of dual tobacco and cannabis cessation. Each study required a 
measure of level of tobacco and cannabis use pre and post intervention.  
When the article indicated that tobacco and cannabis use measures pre and post intervention were 
collected but not reported, authors were contacted to provide separate data for this sub-group of 
participants reporting co-use at baseline.  
Contact with authors 
A total of 25 authors were contacted up to three times. Of these, seven indicated they did not have 
the available data or were unable to provide it, four did not reply and one provided data which could 
not be used as the format was incompatible with other data. Thirteen authors provided data, two of 
whom provided data on two studies (37-49). Three authors provided the original anonymised 
dataset for our analysis and the remainder provided analysed outcome data.  
Data extraction 
Outcome data, characteristics of studies including location, study design, intervention content and 
whole sample demographics were extracted by HW using a data extraction form which was piloted, 
then adapted. Data were extracted from each study and dataset by HW and entered into a CSV file.  
Where authors had provided raw data, the analysis of these data was carried out by HW and both 
extraction and analysis for each of the studies used in the meta-analysis was checked by MD.  
Meta-analysis 
Criteria for inclusion in the meta-analysis was a cessation or reduction outcome in an intervention 
and control condition. In RStudio (50) meta-analyses using Bayesian and traditional frequentist 
methods were performed on eleven RCTs. Bayesian meta-analysis was selected as it provides 
complete information about the credible parameter values, and consequently the probability of any 
given value, and may be more appropriate for a smaller number of studies (51-52).   One limiting 
factor for Bayesian analyses is that they require a prior probability distribution for the parameter of 
interest.  As this is the first review of this type there is no existing empirically based prior 
distribution.  Solutions to this include using broad prior distributions that have minimal effect on the 
data, or use of data from the studies themselves to provide this (51,53).   The latter of these 
solutions was used in this case to maximise the information, which would be diluted by an 
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As this is a relatively novel approach to meta-analysis, traditional frequentist analyses were also 
carried out to allow for comparison and as a sensitivity analysis for the assumptions made in our 
models. 
Cessation outcomes 
The pooled risk ratio for cessation in the intervention group compared to the control group was 
calculated using the metafor package (50), then the bayesmeta package (50) for the Bayesian meta-
analysis.  For informative priors, 1 was used as the minimum risk ratio, and 4 as the standard 
deviation (51). 
Reduction outcomes 
The standardised mean change (SMC) in use of each substance in each condition was calculated. The 
SMC was selected to allow for a variety of pre intervention levels of use and measurement variation 
(i.e. frequency of use versus amount of use). An effect size was calculated then a Bayesian meta-
analysis was carried out again using bayesmeta. The median of the effect size and the standard 
deviation of the median were used as weakly informative priors. 
Sub-group analysis by intervention target was carried out as specified in protocol, intention to treat 
principles were applied across all the meta-analyses using authors’ raw data. Heterogeneity was 
measured using tau (54-55). In all four meta-analyses, a conservative estimate of variance at 0.8 was 
applied, as variance was not available within original study data. Code used for meta-analyses is 
presented in supplementary material (S2). 
Analysis of uncontrolled studies 
Results of uncontrolled studies were extracted and are reported in Figure 2.  
Results 
Included studies 
A total of 6280 study titles were identified through the search process. Duplicates were removed, 
titles reviewed and 123 articles accessed for full-text review. Following the author data request 
process, 20 studies were included. The total number of participants within all 20 studies was 1599, 
on average of 34.5% were female. The selection process is shown in figure 1.  
FIGURE 1  
Selected characteristics of the included studies are presented in table 1.   
TABLE 1 
Characteristics of studies 
Twelve studies were RCTs (39-45, 47, 48, 56-58); and eight were pilot or feasibility, (“uncontrolled”) 
studies (37, 38, 46, 49, 59-62). Fourteen studies were from the US, two from Switzerland, two from 
the UK, one from France and one from Australia. Most participants were recruited from non-
treatment settings including colleges and community settings. Only five studies were located within 
substance use treatment settings; notably none of these were cannabis treatment services. Of the 
total number of participants, 11% were daily tobacco users, and 19% had either cannabis use 
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Intervention content  
Six studies were dual interventions targeting tobacco and cannabis (37, 59-62); seven targeted 
cannabis use (38, 40-43, 45, 49), one targeted tobacco use (47) and six targeted multi-substance use 
(39, 44, 48, 56, 57), including one which focussed on tobacco and heavy alcohol use (44). 
Each dual intervention provided or offered pharmacotherapy in the form of nicotine replacement 
therapy (NRT) or medication such as varenicline alongside a behavioural component. Most dual 
interventions created new manuals for the delivery of co-use treatment, which were based on 
existing resources for both tobacco and cannabis behavioural treatment (58-62), although the extent 
of integration of these resources to address co-use varied. Two studies (60,62) set the same quit 
date for both substances, and one compared simultaneous with sequential quit attempts (58). Most 
studies used contingency management in additional to other behavioural components; some used a 
computer-delivered and mobile-phone delivered interventions (58-59, 61). With one exception (62), 
all interventions were individual. Only one dual intervention was an RCT. 
Cannabis use interventions consisted mainly of behavioural interventions, with only two using 
pharmacological treatment, one of which was an inpatient study (42, 49). The single tobacco use 
intervention employed behavioural components only, delivered via Facebook in both an individual 
and group format (47). The majority of the multi-substance interventions (MSI) were brief, with two 
exceptions (44, 46), one of which delivered a lengthy culturally adapted intervention. 
Outcome measurement across all studies 
Frequency vs amount 
Measurement of tobacco use was relatively standard across all studies, most using cigarettes per day 
(n=14). Measurement of cannabis use was more varied between frequency of use and amount used; 
frequency of days used in past 30 was the most commonly used measure (n=8).  
Type of co-use 
None of the dual studies reported any detailed measurement of co-use, i.e. whether participants 
used both concurrently, or co-administered, although two studies targeting cannabis use did ask 
about co-use (42, 49).  
Biochemical verification 
All brief, single session interventions as well as the single tobacco targeted intervention used self-
report as measures for tobacco and cannabis use at follow-up.  
Of the six dual intervention studies, all used biochemical verification for tobacco cessation, and all 
except one (62) used biochemical verification for cannabis cessation. 
Methods used to verify tobacco abstinence included carbon monoxide testing and saliva and/or 
urine cotinine analysis. Methods used to verify cannabis abstinence were more varied; most used 
urinalysis without specifying cut off points for cannabis levels.   
Meta-analyses of RCTs 
Although intervention format in the twelve RCTs varied, all addressed the same clinical question, i.e. 
efficacy of intervention on change in use of tobacco and cannabis, therefore meta-analyses were 
conducted. One RCT was excluded from the meta-analysis and included in the narrative synthesis 
(58) as the two conditions tested were simultaneous versus sequential dual intervention whereas 
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Measures used in meta-analyses 
Each study measured two, three or four outcomes as indicated in Table 2.  
TABLE 2 
Cessation outcomes  
Meta-analysis of tobacco cessation outcomes shown in Figure 2 (studies = 9) shows a pooled risk 
ratio of 1.10 [Credibility Interval (CrI) 0.68, 1.87].  There was little evidence of heterogeneity 
(Q=8.57, df=8, p=0.6; I2=0.14).  
FIGURE 2 
Meta-analysis of cannabis cessation outcomes shown in Figure 3 (studies=8) shows a pooled risk 
ratio of 1.48 [CrI 0.92, 2.49] indicating a small effect which may be clinically significant.  
Heterogeneity across the nine studies was moderate (Q=11.35, df=7, p=0.9, I2=0.41).   
FIGURE 3 
Frequentist meta-analysis for cessation outcomes was performed. Using a random effects model, 
tobacco cessation risk ratio was 1.07 [0.76, 1.52], p=0.69. For cannabis cessation, pooled risk ratio 
was 1.46 [1.03, 2.09], indicating almost no difference to Bayesian analysis outcomes.  
 
Sub-group analysis 
For tobacco cessation outcomes, subgroup analysis by intervention target showed very little 
difference; the pooled risk ratio for cannabis targeted interventions was 1.10 [0.48, 2.85] and for 
multi-substance interventions 1.25 [0.53, 2.94].  
However, for cannabis cessation outcomes, subgroup analyses did indicate a difference by 
intervention target. Multi-substance interventions showed a significantly positive effect (RR= 2.19 
[1.10, 4.36]), whereas the cannabis targeted interventions mean estimate was similar to the all-
studies outcome, (RR=1.39 [0.75,2.74]). Heterogeneity of sub-group analysis of each substance 
indicated that I2 reduced to 15% and 26% respectively, suggesting it may be explained by differences 
in intervention target.  
 
Reduction outcomes 
Meta-analysis of standardised mean change (SMC) in tobacco use reduction as shown in Figure 4 
(studies = 9) showed no intervention effect at 0.06 [-0.11, 0.23].  Heterogeneity was high (Q=45.55, 
df=8, p=0.5, I2=0.88). 
FIGURE 4 
Meta-analysis of cannabis reduction outcomes shown in Figure 5 (studies = 9) showed a small 
significant effect of 0.25 [0.03, 0.45]. Heterogeneity was also high (Q=59.76, df=8, p=0.8, I2=0.93). 
FIGURE 5 
Frequentist meta-analysis for reduction outcomes was performed. Using a random effects model, 
tobacco reduction effect size estimate was 0.09, p=0.30 and for cannabis the estimate was 0.32, 
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Subgroup analysis 
For tobacco reduction outcomes, subgroup analysis by intervention target made little difference; the 
estimate for cannabis targeted interventions was 0.09 [-0.16, 0.34] and for multi-substance 
interventions 0.04 [0.13, 0.169].  
Similarly, for cannabis reduction outcomes, subgroup analysis did not show any meaningful 
differences by intervention target. For cannabis targeted studies the mean estimate was similar to 
the all studies outcome, at 0.17 [-0.14, 0.45] and by multi-substance interventions at 0.26 [0.03, 
0.54].  
Sensitivity analysis altering the variance in each analysis to 0.2 made no significant difference to any 
of the four outcomes  
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Table 3 shows tobacco and cannabis cessation outcomes for all studies not included in meta-analysis 
in order of sample size.  
TABLE 3 
The data suggest that a higher proportion of people achieved cannabis cessation than tobacco 
cessation, and that cessation of both tobacco and cannabis was relatively rare, even within dual 
studies.  Reduction outcomes are not presented as data were incomplete, but all studies indicated a 
small degree of reduction in both substances. 
Quality appraisal 
Risk of bias summary  
The Risk of Bias summary (supplementary materials S3) indicates that overall the RCT studies are of 
moderate quality. Appraisal of the uncontrolled studies indicates reasonable quality, including high 
rates of biochemical verification amongst the uncontrolled studies compared to RCTs.  
Russell Standard  
Studies targeting tobacco, including the dual interventions showed higher concordance with the 
Russell standard for tobacco abstinence. In the other studies reporting of tobacco outcomes was 
inconsistent.  
Publication bias 
No evidence of asymmetry was seen when trim and fill was used on funnel plot of tobacco cessation 
meta-analysis (see supplementary material S5). However for cannabis cessation, when trim and fill 
was used to add three studies, the risk ratio reduced from 1.46 to 1.18 [0.8, 1.77], suggesting some 
evidence of publication bias.  
For reduction meta-analysis, no evidence of publication bias was observed as estimates within 
funnel plots were very close to original outcomes. Plots are not shown for this reason.  
Discussion 
This is the first systematic review and meta-analysis to look at interventions for tobacco or cannabis 
which have been delivered to co-users. The review has reported on a population previously hidden 
within intervention findings by using unpublished data on co-users provided by authors. Using a 
novel analysis approach, Bayesian meta-analysis of RCTs delivered to co-users showed a small 
positive impact on cannabis cessation which approached significance (1.48 [0.92, 2.49]); but a 
negligible impact on tobacco cessation (1.10 [0.68, 1.87]).  Subgroup analysis indicated that multi-
substance interventions appeared to have a greater impact than cannabis targeted interventions on 
cannabis cessation, which may explain heterogeneity found in analysis. A small intervention effect 
was observed on cannabis reduction (0.25 [0.03, 0.45]) but not tobacco reduction (0.06 [-0.11, 
0.23]). Significant heterogeneity within reduction outcomes was not explained by subgroup analysis 
by intervention target.  
Quality of evidence is considered moderate, and although heterogeneity should be taken into 
consideration, overall the quality of evidence should not influence the validity of the findings.  
Our meta-analysis of tobacco cessation outcomes showed no intervention effect, irrespective of 
intervention target. This contrasts with a recent Cochrane Review of tobacco cessation treatment 
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interventions in our meta-analysis did not include evidence-based tobacco cessation treatment. This 
may partly explain the absence of an effect, in addition to the influence of cannabis use on tobacco 
cessation. An earlier systematic review considering tobacco cessation outcomes within alcohol brief 
interventions also found no intervention effect for tobacco cessation, although brief interventions 
may be less effective in targeting cessation (64). In future interventions, greater attention to types of 
co-use practised is required; for example, co-administration of tobacco and cannabis may increase 
use of the other substance post cessation in comparison to concurrent use.    
Our meta-analysis of cannabis cessation shows an intervention effect lower than that found in the 
Cochrane Review of psychosocial interventions for CUD (RR=2.55, [1.34, 4.83]), although the 
evidence in that review was considered low quality (24). The Cochrane Review of pharmacotherapies 
for cannabis dependence found mixed quality evidence, (RR 0.98, 0.64 to 1.52)(23), comparable to 
the small effect we found. Evidence of asymmetry in the funnel plot for cannabis cessation may be 
explained by a non-reporting bias, although there were no obvious indications of such bias in the 
review process.  However, the large number of authors who didn’t provide data for co-users, and the 
potential for interventions to have measured cannabis use but not reported this, especially in 
tobacco cessation interventions, may indicate a non-reporting bias. Analysis of future studies 
reporting fully on a range of substance use outcomes can address this potential bias.   
Our analysis showed a small effect for cannabis reduction. Cannabis cessation or reduction amongst 
regular users has been characterised as challenging, requiring multiple attempts (65), and 
intervention effects appear small (23, 25), in keeping with our findings. An effect on tobacco 
reduction was not seen in our analysis, although reduction in comparison to cessation is less 
commonly used within tobacco interventions.  
This analysis has used both Bayesian and traditional methods of meta-analysis. Although the results 
are similar, their interpretation is very different; the Bayesian analysis giving both a point estimate 
and full distribution of the parameter in the form of a credible interval.  One of the obstacles to 
undertaking Bayesian analysis is the lack of informative prior distributions, here we have 
demonstrated one solution to this which is to use priors from the data itself.  The more logical 
interpretation of the full posterior distribution may compensate for any limitation relating to the 
absence of prior information.   
The findings from our meta-analysis do not clearly indicate whether single substance use 
interventions are any more or less effective than multi-substance use interventions. Dual studies 
addressing both tobacco and cannabis were identified, although not included in the meta-analysis. 
These demonstrated feasibility and suggest a greater impact on cannabis cessation than tobacco 
cessation, comparable to our meta-analysis findings. Notably, adherence to tobacco cessation 
outcome standards was high in the dual studies, e.g. defining abstinence, which may explain some of 
the differences between tobacco and cannabis outcomes.  Feasibility findings indicate that attention 
must be given to the sampling frame as community settings appear more successful for recruitment 
than substance misuse settings. Motivation may be a barrier to recruitment; an intervention to 
address this prior to commencing recruitment for treatment appeared effective (66).  
This review has also highlighted methodological issues with the literature. First, a large number of 
studies were excluded as they did not measure use of both substances pre and post intervention, or 
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challenging on the basis of cost, but self-report measures are of value, and easily obtainable. The 
availability of such data would allow for further investigation by secondary analysis of the role of co-
use in single and multi-substance intervention studies, and would strengthen the evidence base for 
addressing these commonly used substances.  
Second, measurement of co-use, including whether concurrent and/or co-administered would   
reduce potential bias and provide detail and context of use behaviours (67-68).  Participants in 
studies may under-report co-use, for example when asked about cannabis may ignore tobacco used 
in joints. Specific patterns of co-use may be associated with higher levels of dependency on either 
substance, and with varying success of cessation or reduction of either substance.  
Third, no studies within this review reported measuring cannabis type or potency. Literature 
indicates that potency may play a significant factor in the experience of adverse effects and the 
development of CUD (69). Differences between frequency and amount of cannabis use presents a 
further challenge in reviewing studies, and both concepts are subject to recall bias (70-71). Tobacco 
cessation outcome reporting has been set out in the Russell Standard; cannabis studies which 
measure tobacco use would benefit from adherence to these guidelines (35), and from a set of 
cannabis reporting standards. Measurement of cannabis use requires further discussion and 
consensus development within the field (72); this process has begun (73).  
This review contains limitations and has only partially met its objectives. The number of studies in 
the meta-analysis is small, most studies primarily targeted cannabis, and most participants were 
male. The lack of tobacco targeted studies is a significant limitation, and should be taken into 
account when considering the greater impact seen on cannabis targeted studies. Future 
interventions which target either but measure both can be added to the data to expand on these 
conclusions. Unfortunately, no RCTs which targeted co-use could be included in the meta-analyses; 
hopefully these will be developed. Evidence of potential compensatory use of the second substance 
post intervention of the primary substance was not available, and also limits our ability to draw 
conclusions about the efficacy of single vs. dual interventions on use of both substances. This data 
should be made available in future intervention studies, allowing for an investigation of potential 
compensatory use.  
Due to time constraints, only one author conducted the initial screening process, potentially 
increasing the risk of selection bias. Additionally, we contacted a large number of authors (n=25), of 
whom only thirteen provided data. Older datasets were less likely to be available, however changes 
in cannabis potency in the last few decades indicate that more recent data is likely to be most 
relevant (74).  
Although heterogeneity of intervention targets has been explored within the sub-group analysis, 
other sources include variability of measurement, as discussed previously, differences in duration of 
intervention and biochemical verification of cessation.  Further sensitivity analyses across other 
domains may indicate the source of the heterogeneity, although were not planned in this review.  
Most of the evidence reviewed was from the US, though patterns of both cannabis use and co-use 
vary significantly worldwide (75). Inadequate measurement of types of co-use limits the transfer of 
these findings to other countries. One study adapted materials for a specific population (46) but 
further discussion of how socio-cultural influences pertaining to tobacco and cannabis use may 
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tobacco, nicotine, and cannabis in its many forms may elicit changes in co-use practises such as co-
administration and future intervention studies need to take these complexities into account. This 
requires scrutiny across all populations, including those from more deprived populations where 
more harmful methods of tobacco and cannabis use may prevail. 
Future research should consider the theoretical framework required for addressing use of two 
closely related substances. The theoretical basis of interventions was described by some studies in 
our review, but most dual interventions adapted existing materials for either substance, delivered 
concurrently. As the theoretical basis for dual interventions is yet to be fully developed, it is not 
known whether delivering a tobacco intervention alongside a cannabis intervention results in a 
different outcome to an intervention which seek to integrate treatment of both. The single study in 
this review to evaluate simultaneous versus sequential dual treatment was inconclusive. Further 
research using more intensive tobacco treatment interventions is also warranted.  
Conclusions 
Dual interventions for tobacco and cannabis co-use have demonstrated feasibility. Meta-analysis of 
treatment interventions targeting tobacco and/or cannabis use showed a small intervention effect 
on cannabis reduction but not on tobacco reduction. No significant effect was seen on tobacco 
cessation or cannabis cessation. Further research is required to extricate potential reasons for poor 
outcomes amongst co-users. 
Outcomes for co-use of tobacco and cannabis need routine measurement to fully account for the 
potential impact of co-use in both tobacco and cannabis specific interventions. Interventions must 
collect details of type of co-use practised, as well as fuller details of cannabis use. 
RCTs of dual interventions are required to address co-use. Future dual interventions should ensure 
that tobacco dependence is fully measured and that adequate tobacco cessation treatment is 
provided.  
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Single session 14 4.8% 
Key: AE; Aerobic Exercise; ART: Abstinence Reinforcement Therapy; ASU: Assessment of substance use; BI: Brief Intervention; BMI: Brief Motivational Interviewing; C: cannabis; CAIT: 
Computer-assisted Individual Therapy; CaseM: Case Management; CBT: Cognitive Behaviour Therapy; CM: Contingency management; CPD: cigarettes per day; CUD: cannabis use disorder;; 
DIA: Drug information and advice; DSM: Diagnostic and Statistical Manual; OGT: Online group; GT: Group therapy; IT: Individual therapy; Li: Lithium carbonate; MAT: Medication assisted 
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Table 2 Outcome measures used for each RCT included in meta-analysis. CPD =cigarettes per day, past 30 days = days of use 




(BV) or self-reported 
(SR) 
Cannabis cessation  









Laporte 2017 (41) - - cigarettes per 
week  
joints per month 12 months  
Kadden 2007 (40) SR BV CPD 
 
joints per day 14 months  
McCambridge 2008 
(43) 
SR SR CPD 
 
past 30 days 6 months  
McClure 2014 (42) BV BV CPD - 
 
8 weeks  
Peters 2013 (45) - - days used in past 
28 
past 30 days 
 
13 months  
Gmel 2013 (39) SR SR CPD past 30 days 6 months  
McCambridge 2004 
(56) 
SR SR cigarettes per 
week 
frequency of use 
per week 
12 weeks  
Metrik 2011 (44) BV - - past 30 days 26 weeks  
White 2007 (48) SR SR CPD frequency of use in 
past month 
15 months  
White 2008 (57) SR SR CPD frequency of use in 
past month 
7 months  
Vogel 2018 (47) SR SR - - 12 weeks  
Total number of 
participants 
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Table 3 Outcomes of tobacco and cannabis cessation within studies excluded from meta-analysis; 








































































Becker 2015 (61) T&C 77 6 months 4 (7.8) 8 (10.4) 15 (19.5) 
Lee 2019 (58) T&C 67 12 weeks - 6 (17.6) 7 (20.6) 
Lee 2015 (61) T&C 32 12 weeks 0 4 (12.5) 14 (44) 
Winstock 2009 (49) C 13 12 weeks 0 0 3 (23) 
Hill 2013 (60) T&C 7 10 weeks 0 0 0 
Adams 2018 (37) T&C 6 8 weeks 0 0 1(14) 
Buchowski 2011 (38) C 6 4 weeks 0 0 0 
Beckham 2018 (59) T&C 5 6 months 1 (20) 0 1 (20) 
Venner 2016 (46) MSI 3 8 months 0 3 (100) 0 
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Figure 2 Tobacco cessation 
 
Heterogeneity: Q= 8.57, df=8, p=0.6, I2=0.14, n=1050 
Key: ‘Intervention’ = number who quit in intervention group/total in group; ‘control’ = number who quit in control 
group/total in group; intervention target shown in brackets after study name; CrI = Credibility Interval. NB not all studies 
targeted both substances 
 
Figure 3 Cannabis cessation 
 
Heterogeneity: Q=11.35, df=7, p=0.9, I2=0.41, n=1028 
Key: ‘Intervention’ = number who quit in intervention group/total in group; ‘control’ = number who quit in control 
group/total in group; intervention target shown in brackets after study name; CrI = Credibility Interval.  NB not all studies 
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Figure 4 Tobacco reduction 
 
Heterogeneity: Q= 45.55, p value= 0.5, I2=0.88, n=1068 
 
Figure 5 Cannabis reduction 
 
Heterogeneity: Q=59.76, p value = 0.8, I2= 0.93, n=1103 
 
